argenx SE (NASDAQ:ARGX) is one of the Best Extremely Profitable Stocks to Buy Right Now. On June 30, argenx SE (NASDAQ:ARGX) announced its plans to move its experimental drug ARGX-119 into a registrational study for congenital myasthenic syndromes. This decision comes after positive results from a Phase 1b clinical trial.
ARGX-119 is a novel antibody targeting muscle-specific kinase. It’s designed to help patients with congenital myasthenic syndromes. The Phase 1b trial tested ARGX-119 against a placebo in patients with DOK7-CMS, a critically affected subgroup. The results showed that patients receiving ARGX-119 consistently improved on indicators including walking ability, muscle strength, and activities of daily living.
A lab setting filled with scientific equipment and researchers in lab coats working together to develop new therapies for autoimmune diseases.
argenx SE is a biopharmaceutical company that develops innovative antibody therapies to treat severe autoimmune diseases and cancer.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
